5.43
price down icon4.90%   -0.28
after-market Handel nachbörslich: 5.44 0.01 +0.18%
loading
Schlusskurs vom Vortag:
$5.71
Offen:
$5.62
24-Stunden-Volumen:
564.82K
Relative Volume:
2.45
Marktkapitalisierung:
$272.72M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-76.41M
KGV:
-2.8281
EPS:
-1.92
Netto-Cashflow:
$-64.56M
1W Leistung:
-14.35%
1M Leistung:
-27.60%
6M Leistung:
-37.73%
1J Leistung:
-24.27%
1-Tages-Spanne:
Value
$5.28
$5.74
1-Wochen-Bereich:
Value
$5.28
$6.455
52-Wochen-Spanne:
Value
$5.28
$12.38

Aura Biosciences Inc Stock (AURA) Company Profile

Name
Firmenname
Aura Biosciences Inc
Name
Telefon
(617)500-8864
Name
Adresse
80 GUEST STREET, BOSTON
Name
Mitarbeiter
106
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-24
Name
Neueste SEC-Einreichungen
Name
AURA's Discussions on Twitter

Vergleichen Sie AURA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
AURA
Aura Biosciences Inc
5.43 272.72M 0 -76.41M -64.56M -1.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-07-25 Eingeleitet H.C. Wainwright Buy
2023-07-27 Eingeleitet Scotiabank Sector Outperform
2023-04-17 Fortgesetzt BTIG Research Buy
2022-07-19 Eingeleitet JMP Securities Mkt Outperform

Aura Biosciences Inc Aktie (AURA) Neueste Nachrichten

pulisher
Apr 02, 2025

Aura Biosciences expands board with oncology leader By Investing.com - Investing.com South Africa

Apr 02, 2025
pulisher
Apr 02, 2025

Aura Biosciences Announces Appointment Of Teresa Bitetti To Board Of Directors - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Aura Biosciences expands board with oncology leader - Investing.com India

Apr 02, 2025
pulisher
Apr 02, 2025

Aura Biosciences Expands Board with New Director Appointment - TipRanks

Apr 02, 2025
pulisher
Apr 02, 2025

Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors - GlobeNewswire

Apr 02, 2025
pulisher
Apr 02, 2025

Major Leadership Move: Takeda's Oncology Chief Strengthens Aura Biosciences' Commercial Strategy - Stock Titan

Apr 02, 2025
pulisher
Mar 31, 2025

Aura Biosciences stock hits 52-week low at $5.75 amid market challenges By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Aura Biosciences stock hits 52-week low at $5.75 amid market challenges - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

Are Investors Keen On Selling Holdings In Aura Biosciences Inc (NASDAQ: AURA)? - stocksregister.com

Mar 31, 2025
pulisher
Mar 29, 2025

(AURA) Long Term Investment Analysis - news.stocktradersdaily.com

Mar 29, 2025
pulisher
Mar 28, 2025

Q1 Earnings Estimate for AURA Issued By HC Wainwright - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Aura Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

Institutional investors may adopt severe steps after Aura Biosciences, Inc.'s (NASDAQ:AURA) latest 20% drop adds to a year losses - Simply Wall St

Mar 27, 2025
pulisher
Mar 27, 2025

Aura Biosciences Inc: Promising Clinical Progress and Financial Stability Justify Buy Rating - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

What is HC Wainwright’s Forecast for AURA Q3 Earnings? - Defense World

Mar 27, 2025
pulisher
Mar 27, 2025

Aura Biosciences Stock (AURA) Continues to Slide Despite Promising Clinical Progress - markets.businessinsider.com

Mar 27, 2025
pulisher
Mar 26, 2025

Aura Biosciences price target lowered to $19 from $21 at Citizens JMP - TipRanks

Mar 26, 2025
pulisher
Mar 26, 2025

Character Biosciences gains $93m for precision eye disease therapies - Pharmaceutical Technology

Mar 26, 2025
pulisher
Mar 26, 2025

Bel-sar shows promising safety, efficacy in NMIBC - Urology Times

Mar 26, 2025
pulisher
Mar 26, 2025

Aura Biosciences stock target cut to $19 by JMP Securities - Investing.com UK

Mar 26, 2025
pulisher
Mar 26, 2025

Aura Biosciences Reports Progress in Cancer Trials - TipRanks

Mar 26, 2025
pulisher
Mar 25, 2025

Aura Biosciences Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView

Mar 25, 2025
pulisher
Mar 25, 2025

Aura Biosciences stock target raised to $25 by H.C. Wainwright - Investing.com UK

Mar 25, 2025
pulisher
Mar 25, 2025

Promising Clinical Data and Abscopal Effect Drive Buy Rating for Aura Biosciences Inc. - TipRanks

Mar 25, 2025
pulisher
Mar 24, 2025

Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Aura Biosciences Reports Positive Phase 1 Trial Results in Non-Muscle Invasive Bladder Cancer and Advances Clinical Pipeline - Nasdaq

Mar 24, 2025
pulisher
Mar 24, 2025

Aura's Cancer Drug Delivers Complete Responses as $151M Cash Runway Extends to 2026 - Stock Titan

Mar 24, 2025
pulisher
Mar 24, 2025

Promising Phase 1 Results for Aura Biosciences’ Bel-sar in Bladder Cancer Boost Buy Rating - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Aura reports promising bladder cancer trial results By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Aura Biosciences stock hits 52-week low at $6.58 amid market shifts - Investing.com Australia

Mar 24, 2025
pulisher
Mar 24, 2025

Buy Recommendation for Aura Biosciences: Promising Phase 1 Trial Results and Dual Mechanism of Action in Bladder Cancer Treatment - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Aura Biosciences stock hits 52-week low at $6.58 amid market shifts By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Buy Rating for Aura Biosciences Inc. Driven by Promising Phase 1 Trial Results and Future Revenue Potential - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Aura Biosciences Reports 'Robust' Anti-Tumor Immune Response From Phase 1 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer - MarketScreener

Mar 24, 2025
pulisher
Mar 24, 2025

Aura reports promising bladder cancer trial results - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

Aura Biosciences announces data from Phase 1 trial of bel-sar in NMIBC - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Positive Data from Phase 1 Trial of Bel-sar in Patients - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Breakthrough: New Bladder Cancer Drug Achieves 80% Response Rate in Clinical Trial - Stock Titan

Mar 24, 2025
pulisher
Mar 24, 2025

With 48% stake, Aura Biosciences, Inc. (NASDAQ:AURA) seems to have captured institutional investors' interest - Yahoo Finance

Mar 24, 2025
pulisher
Mar 21, 2025

Aura Biosciences, Inc. (NASDAQ:AURA) Sees Large Decrease in Short Interest - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

Analysts Set Groupon, Inc. (NASDAQ:GRPN) PT at $17.33 - Defense World

Mar 20, 2025
pulisher
Mar 20, 2025

Innovative Industrial Properties, Inc. (NYSE:IIPR) Receives $102.00 Average Target Price from Analysts - Defense World

Mar 20, 2025
pulisher
Mar 20, 2025

Aura Biosciences, Inc. (NASDAQ:AURA) Receives $23.00 Consensus Target Price from Brokerages - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Learn to Evaluate (AURA) using the Charts - news.stocktradersdaily.com

Mar 19, 2025
pulisher
Mar 19, 2025

Aura Biosciences (AURA) to Release Quarterly Earnings on Wednesday - Defense World

Mar 19, 2025
pulisher
Mar 16, 2025

Teladoc (TDOC) Harnesses AI for Diabetes Care, Stock Rises 6.7% - MSN

Mar 16, 2025
pulisher
Mar 06, 2025

TCR Therapy Clinical Trial Pipeline Accelerates as 80+ - GlobeNewswire

Mar 06, 2025
pulisher
Mar 05, 2025

Tarsus Pharmaceuticals (NASDAQ:TARS) & Aura Biosciences (NASDAQ:AURA) Critical Survey - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

H.C. Wainwright maintains $22 target on Aura Biosciences stock By Investing.com - Investing.com UK

Mar 04, 2025
pulisher
Mar 03, 2025

Buy Rating for Aura Biosciences Driven by Promising Bel-sar Developments and Market Potential - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Promising Developments in Aura Biosciences Inc’s Clinical Trials Lead to Buy Rating - TipRanks

Mar 03, 2025

Finanzdaten der Aura Biosciences Inc-Aktie (AURA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Kapitalisierung:     |  Volumen (24h):